Drug Profile
Supaglutide - Innogen Pharmaceutical Technology
Alternative Names: Diabegone; Supaglutide injection - Shanghai Innogen Pharmaceutical TechnologyLatest Information Update: 06 Nov 2023
Price :
$50
*
At a glance
- Originator St. Michaels Hospital; University of Toronto
- Developer Yinnuo Pharmaceutical Technology
- Class Antihyperglycaemics; Recombinant fusion proteins
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Type 2 diabetes mellitus
Most Recent Events
- 02 Oct 2023 Adverse events and efficacy data from a phase-II/III trial in Type 2 diabetes mellitus presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD-2023)
- 02 Oct 2023 Adverse events and efficacy data from a phase-II/III trial in Type 2 diabetes mellitus presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD-2023)
- 23 Jun 2023 Adverse events and efficacy data from a phase-II/III trial in Type 2 diabetes mellitus presented at the 83rd Annual Scientific Sessions of the American Diabetes Association (ADA-2023) (SC)